Grifols (WBO:GRF) FFO


WBO:GRF Grifols SA WBO:GRF
83 GF Score
Price €9.11
GF Value €10.93
! 6 Warning Signs
View Full Analysis

What is Grifols FFO?

FFO (Funds from operations) only applies to REITs.

WBO:GRF
83GF Score
Grifols SA WBO:GRF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Grifols (WBO:GRF) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of €9.11 is trading 16.6% below its estimated GF Value™ of €10.93.

Key valuation signals for WBO:GRF:

  • FFO:
  • GF Value™: €10.93 vs. price of €9.11 (16.6% below fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the WBO:GRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
83GF Score

Get the complete analysis for WBO:GRF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.11
Price
€10.93
GF Value